Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 28, 2020

View Archived Issues

Targeting GCGR signaling pathway counteracts PI3K inhibitor-induced hyperglycemia

DISC-0974 decreases hepcidin and increases transferrin saturation in inflammation models

First-in-human data presented for talquetamab in patients with RRMM

Results of RCT evaluating nilotinib in patients with moderately advanced Parkinson's disease

DISC-A demonstrates efficacy in low hepcidin rat model

CTPS2 as novel prognostic biomarker in CLL

FDA lifts clinical hold on ASPIRO study of AT-132

Orelabrutinib approved in China for two cancer indications

Shanghai Institute of Materia Medica, Fudan University patent PD-1/PD-L1 interaction inhibitors

First subject dosed in phase I study of ASC-42

National Institute of Pharmaceutical R&D describes M3 antagonists/beta2-adrenoceptor agonists

New autotaxin inhibitors described by Jiangsu Hengrui Medicine, Shanghai Hengrui Pharmaceutical

Medshine Discovery synthesizes new JAK1/JAK2 inhibitors

New ERK inhibitors discovered at Hutchison MediPharma

Byvasda approved in China the treatment of recurrent glioblastoma

Arctic Vision obtains IND approval for ARVN-001 in China

NX-2127 shows promising antitumor activity in models of B-cell malignancies

Enrollment ongoing in phase II study of PHA-022121

Nociceptive neurons shown to boost hematopoiesis

Geron initiates phase III study of imetelstat in myelofibrosis refractory to JAK inhibitors

ZyCoV-D vaccine candidate demonstrates safety and immunogenicity in phase I/II study

Primary endpoint not met in phase III trial of eprenetapopt in TP53-mutant myelodysplastic syndromes

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...
DEE-lightful: Praxis’ phase II results allow stock to flex its muscle
BioWorld
Positive efficacy results led to Praxis Precision Medicines Inc.’s phase II Embold study in developmental and epileptic encephalopathies (DEEs) being halted...